Clearside Biomedical, Inc. (NASDAQ:CLSD – Get Rating) CFO Charles A. Deignan sold 14,030 shares of the business’s stock in a transaction dated Thursday, January 19th. The stock was sold at an average price of $1.50, for a total transaction of $21,045.00. Following the sale, the chief financial officer now directly owns 363,472 shares in the company, valued at $545,208. The sale was disclosed in a legal filing with the SEC, which is available through this link.
Clearside Biomedical Stock Performance
Shares of CLSD opened at $1.50 on Monday. Clearside Biomedical, Inc. has a 52 week low of $0.98 and a 52 week high of $2.85. The firm has a market cap of $90.29 million, a P/E ratio of -18.75 and a beta of 1.83. The firm’s 50-day simple moving average is $1.27 and its 200 day simple moving average is $1.35.
Clearside Biomedical (NASDAQ:CLSD – Get Rating) last announced its quarterly earnings results on Wednesday, November 9th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.17). Clearside Biomedical had a negative net margin of 17.15% and a negative return on equity of 16.13%. The company had revenue of $0.27 million during the quarter, compared to analyst estimates of $16.50 million. As a group, equities analysts forecast that Clearside Biomedical, Inc. will post -0.52 earnings per share for the current year.
Institutional Inflows and Outflows
Analysts Set New Price Targets
CLSD has been the topic of several analyst reports. HC Wainwright boosted their price target on shares of Clearside Biomedical from $5.00 to $6.00 and gave the stock a “buy” rating in a research report on Thursday, November 10th. StockNews.com initiated coverage on shares of Clearside Biomedical in a research report on Friday, November 4th. They set a “hold” rating on the stock. Needham & Company LLC raised shares of Clearside Biomedical from a “hold” rating to a “buy” rating and set a $5.00 price target on the stock in a research report on Thursday, November 10th. Finally, Stifel Nicolaus raised shares of Clearside Biomedical from a “hold” rating to a “buy” rating and set a $8.00 target price on the stock in a report on Wednesday, November 9th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $7.60.
Clearside Biomedical Company Profile
Clearside Biomedical, Inc is a biopharmaceutical company, which delivers therapies to the back of the eye through the suprachoroidal space. Its pipeline include CLS-AX, Integrin Inhibitor, and gene therapy. The company was founded by Samir Kumar Patel, Vladimir Zarnitsyn, Mark Prausnitz, Daniel H. White, and Henry F.
- Get a free copy of the StockNews.com research report on Clearside Biomedical (CLSD)
- CVS Health is Growing into an Integrated Healthcare Organization
- NVIDIA Outlook Improving: Watchlist Candidate for 2023
- Is C3.ai Stock a ChatGPT Artificial Intelligence Play?
- Which Wireless Stock Should You Buy in 2023?
- Is Virgin Galactic Stock Preparing for Lift-Off?
Receive News & Ratings for Clearside Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.